Comparative Pharmacology
Head-to-head clinical analysis: RIOMET versus RIOMET ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIOMET versus RIOMET ER.
RIOMET vs RIOMET ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Oral, 500 mg twice daily or 850 mg once daily, increased gradually to 2000 mg daily in divided doses.
Oral, 500 mg once daily, increase by 500 mg weekly to maximum 2000 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 6.2 hours (range 4–12 hours); clinical context: 4–5 half-lives to steady state (approx 24–36 hours); prolonged in renal impairment (e.g., creatinine clearance <60 mL/min contraindicated)
Terminal elimination half-life is approximately 6.2 hours in patients with normal renal function; prolonged to up to 17.6 hours in renal impairment (eGFR <30 mL/min).
Renal (90% unchanged via glomerular filtration and tubular secretion); fecal (10%)
Renal elimination of unchanged drug accounts for approximately 90% of an absorbed dose; fecal excretion is minimal (<5%).
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic